Dare Bioscience

DARE74

Penny Stock

$3.34arrow_drop_up4.02%$0.12

Penny Stock

DARE74

$3.34

arrow_drop_up4.02%$0.12

Penny Stock

Performance History

Key Stats
Open	$3.23
Prev. Close	$3.23
EPS	-0.58
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$29.05M
PE Ratio	-

	LOW	HIGH
Day Range	3.20	3.42
52 Week Range	3.05	7.56

Ratios







EPS	-0.58

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Dare Bioscience (DARE)

Dare Bioscience Inc (DARE) is a pharmaceutical company focused on the development and commercialization of innovative products in women's health. The company's mission is to improve the lives of women by addressing unmet needs in this underserved market. With a strong pipeline of potential products, Dare Bioscience is well-positioned for growth and success in the coming years.

The stock price history of Dare Bioscience Inc shows both volatility and potential for long-term growth. Over the past year, the stock has experienced fluctuations but has generally trended upwards. Investors should carefully consider the company's financials and market conditions before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Sabrina Martucci Johnson
Headquarters: San Diego
Employees: 25
Exchange: NASDAQ

Keep an eye on Dare Bioscience

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Dare Bioscience 's (DARE) price per share?

The current price per share for Dare Bioscience (DARE) is $3.34. The stock has seen a price change of $0.13 recently, indicating a 4.02% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Dare Bioscience (DARE)?

For Dare Bioscience (DARE), the 52-week high is $7.56, which is 126.35% from the current price. The 52-week low is $3.05, the current price is 9.51% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Dare Bioscience (DARE) a growth stock?

Dare Bioscience (DARE) has shown an average price growth of -4.13% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Dare Bioscience as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Dare Bioscience (DARE) stock price performance year to date (YTD)?

As of the latest data, Dare Bioscience (DARE) has a year-to-date price change of -15.37%. Over the past month, the stock has experienced a price change of -9.97%. Over the last three months, the change has been -2.34%. Over the past six months, the figure is -30.42%. Looking at a longer horizon, the five-year price change stands at -66.03%.

help

Is Dare Bioscience (DARE) a profitable company?

Dare Bioscience (DARE) has a net income of -$30.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -32.8K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.81M, although specific revenue growth data is currently not available. The gross profit is $2.77M. Operating income is noted at -$30.84M. Furthermore, the EBITDA is -$26.7M.

help

What is the market capitalization of Dare Bioscience (DARE)?

Dare Bioscience (DARE) has a market capitalization of $29.06M. The average daily trading volume is 3.28, indicating the stock's liquidity and investor engagement.

News

DARÉ BIOSCIENCE

SILDENAFIL CREAM

FEMALE SEXUAL AROUSAL DISORDER

PATIENT-REPORTED OUTCOMES

Aug 13, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Dare Bioscience regains Nasdaq compliance with bid price - Investing.com

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewswire